Pure Global AI
NCT05492877Not yet recruiting

An Efficacy and Safety Study of AZD4831 (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

A Phase 2a Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
AstraZenecaPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Drug/Device/Intervention
AZD4831
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
AstraZeneca
Timeline & enrollment
Phase
Phase 2
Start date
Nov 06, 2022
End date
Apr 12, 2024
Enrollment
288 participants
Primary outcome

To evaluate the effect of AZD4831 as compared to placebo on the time to first COPD Composite Exacerbation (CompEx) event.

Summary

This is a research study to evaluate the efficacy and safety of the investigational drug
 AZD4831 in adult participants with chronic obstructive pulmonary disease.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05492877
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05492877 through Pure Global AI's free database. This Phase 2 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 288 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.